Investors Buy Gilead Sciences, Inc. (GILD) on Weakness

Investors purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading on Friday. $116.06 million flowed into the stock on the tick-up and $84.61 million flowed out of the stock on the tick-down, for a money net flow of $31.45 million into the stock. Of all stocks tracked, Gilead Sciences had the 28th highest net in-flow for the day. Gilead Sciences traded down ($1.37) for the day and closed at $82.14

A number of research firms have recently weighed in on GILD. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Vetr downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective for the company. in a report on Monday, September 4th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a report on Friday. Twelve equities research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $85.66.

The stock has a market cap of $107.27 billion, a price-to-earnings ratio of 8.92 and a beta of 1.14. The stock has a 50 day moving average price of $80.97 and a 200 day moving average price of $71.66.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the prior year, the firm posted $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.75 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

In other news, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total value of $2,960,000.00. Following the sale, the executive vice president now owns 137,488 shares of the company’s stock, valued at $10,174,112. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now directly owns 106,113 shares in the company, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. In the last three months, insiders sold 486,819 shares of company stock worth $39,298,919. Insiders own 1.30% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of GILD. Parnassus Investments CA grew its holdings in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after purchasing an additional 2,727,063 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after purchasing an additional 2,700,600 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Gilead Sciences by 50.0% in the second quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock worth $438,244,000 after purchasing an additional 2,062,886 shares during the last quarter. Hedge funds and other institutional investors own 73.99% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/investors-buy-gilead-sciences-inc-gild-on-weakness/1699710.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.